VX-659

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 1

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

CompletedNCT03029455

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2016-11-30End: 2017-08-31Updated: 2017-09-05

Phase 2

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

CompletedNCT03224351

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2017-08-08End: 2018-02-28Updated: 2021-04-22

Related Papers

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine2018-10-18320 citations